New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer

Nature Reviews Clinical Oncology volume 23 , pages 566–568 ( 2026 ) Cite this article

The therapeutic landscape of platinum-resistant ovarian cancer is rapidly evolving, with recent phase III trials demonstrating, for the first time, meaningful overall survival improvements beyond bevacizumab-based therapy. Herein we discuss how trials such as MIRASOL and, more recently, ENGOT-ov65/KEYNOTE-B96 and GOG30173/ENGOT-ov72/ROSELLA have established new standards of care through distinct biologically driven therapies and outline the new challenges that these approaches expose.

González-Martín, A. et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34 , 833–848 (2023).

Pujade-Lauraine, E. et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol. 32 , 1302–1308 (2014).

Moore, K. N. et al. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N. Engl. J. Med. 389 , 2162–2174 (2023).

Colombo, N. et al. Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study. Lancet 407 , 1525–1537 (2026).

Lorusso, D. et al. Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial. Lancet 407 , 1513–1524 (2026).

Vida, R. et al. Immunotherapy with anti-PD-1 or PD-L1 in advanced ovarian cancer: a meta-analysis of randomized trials. Cancer Treat. Rev. 144 , 103094 (2026).

Ray-Coquard, I. et al. LBA42 Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): primary analysis of the phase II dose-optimization part of REJOICE-Ovarian01. Ann. Oncol. 36 , S1585–S1586 (2025).

Damian, S. et al. Safety and preliminary efficacy from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with advanced platinum-resistant and refractory ovarian cancer (OC). J. Clin. Oncol. 43 , abstr. 5514–5514 (2025).

Simpkins, F. et al. Cyclin E1 as a predictive biomarker of azenosertib benefit in platinum-resistant ovarian cancer: outcomes from part 1b of the DENALI study (GOG-3066). Gynecol. Oncol. 200 , abstr. 8–9 (2025).

The drafts for Fig. 1 and Supplementary Fig. 1 were generated using Claude (Anthropic, Claude Opus 4.7), based on data extracted from the cited primary publications. The authors verified all data points and take responsibility for figure accuracy.

I.R.C. is a scientific advisory board member and/or consultant for Abbvie, Agenus, Antares, AstraZeneca, BMS, BioNTech, BeOne, Corcept, Daiichi-Sankyo, Deciphera, ESAI, Genmab, GSK, Immunocore, Incyte, Janssen, Lilly, Macrogenics, Merck, Novartis, OSE Pharma, Pharma&, Pfizer, Regeneron, Tubulis, Verastem and Zentalis; and has had leadership roles with ENGOT Network (Chair), ESGO (Council member) and GINECO group (past Chair). K.N.M. is a scientific advisory board member and/or consultant for Aadi, Abbvie, AstraZeneca, BioNTech, BeOne, Corcept, Caris, Daiichi-Sankyo, Genmab, GSK, Immatics, Immunocore, Immunogen, Incyte, Janssen, Merck, Regeneron, Schrodinger, Takeda, Tubulis, Verastem, Whitehawk, Zentalis and Zymeworks; has developed educational content and/or been a speaker for Oncology Learning Network, Physicians Education Resource, PRIME and Research to Practice; and has had leadership roles with ASCO (Board of Directors and Treasurer), GOG Foundation (Board of Directors), GOG Partners (Associate Director) and NRG (Ovarian Committee Chair).

Ray-Coquard, I., Moore, K.N. New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer. Nat Rev Clin Oncol 23 , 566–568 (2026). https://doi.org/10.1038/s41571-026-01168-5